This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Head and neck squamous cell carcinoma | |
|---|---|
| Name | Head and neck squamous cell carcinoma |
| Types | Oropharyngeal, laryngeal, hypopharyngeal, oral cavity |
| Icd10 | C00–C14, C32 |
| Presents | Lump, sore throat, dysphagia |
| Risk factors | Tobacco, alcohol, human papillomavirus |
| Treatment | Surgery, radiotherapy, chemotherapy, immunotherapy |
| Prognosis | Variable by stage and HPV status |
Head and neck squamous cell carcinoma
Head and neck squamous cell carcinoma is a group of malignant neoplasms arising from the mucosal epithelium of the oral cavity, pharynx, and larynx. It presents variably depending on subsite and stage and has distinct epidemiologic patterns related to tobacco, alcohol, and viral exposures. Management frequently requires coordination among surgical, radiation, and medical oncology teams and involves complex functional and reconstructive considerations.
Patients commonly present with a persistent Lochmaben-type mass such as a neck lump, nonhealing oral ulcer, or hoarseness; associated findings include odynophagia, dysphagia, otalgia, and bleeding. Early lesions may be asymptomatic while advanced disease produces weight loss, airway compromise, or neurologic deficits from cranial nerve involvement; sentinel clinical signs are evaluated by teams at tertiary centers like Mayo Clinic, Memorial Sloan Kettering Cancer Center, and MD Anderson Cancer Center. Physical findings include mucosal erythroplakia or leukoplakia, fixed cervical adenopathy, and fungating tumors that prompt referral to specialists associated with institutions such as Johns Hopkins Hospital and Cleveland Clinic. Symptom trajectories often bring patients through emergency departments, primary care clinics affiliated with Kaiser Permanente or academic settings like Massachusetts General Hospital for diagnostic workup.
Major risk factors include exposure to combustible tobacco and heavy alcohol use observed in populations studied by organizations such as World Health Organization, Centers for Disease Control and Prevention, and International Agency for Research on Cancer. Infection with high‑risk human papillomavirus types, especially HPV‑16, is a dominant etiologic agent for oropharyngeal tumors described in cohorts from Johns Hopkins University and University of California, San Francisco. Occupational exposures and betel nut chewing are implicated in geographic clusters reported in studies from Bangladesh, India, and Taiwan. Host factors such as immunosuppression after solid organ transplantation or HIV infection are recognized by guidelines from National Comprehensive Cancer Network and populations treated at centers like Royal Marsden Hospital.
Carcinogenesis involves stepwise accumulation of genetic and epigenetic alterations in squamous epithelium, with loss of TP53 function, CDKN2A inactivation, and deregulation of the EGFR pathway described in seminal papers from institutions including Cold Spring Harbor Laboratory, Broad Institute, and Sanger Institute. HPV‑positive tumors characteristically express viral oncoproteins E6 and E7 that inactivate p53 and RB1, producing a distinct molecular signature investigated through consortia such as The Cancer Genome Atlas and studied in laboratories at Dana-Farber Cancer Institute. Aberrant signaling through PI3K/AKT/mTOR, NOTCH1 mutations, and alterations in chromatin regulators are common; tumor microenvironment features, including immune checkpoint ligand expression (PD‑L1), inform therapeutic strategies developed by pharmaceutical firms like Bristol Myers Squibb and Merck & Co.. Patterns of clonal evolution, field cancerization, and stromal interactions have been explored in translational programs at Stanford University and University of Cambridge.
Diagnosis is confirmed by endoscopic visualization and histopathologic examination with biopsy performed by otolaryngologists and head and neck surgeons at centers such as Guy's Hospital and Royal College of Surgeons. Imaging modalities used for staging include contrast CT, MRI, and PET‑CT assessed by radiology departments at Charité – Universitätsmedizin Berlin and Karolinska University Hospital. Staging follows the TNM classification promulgated by the Union for International Cancer Control and American Joint Committee on Cancer, with p16 immunohistochemistry serving as a surrogate marker for HPV status per guidelines from bodies like College of American Pathologists. Multidisciplinary tumor boards at institutions such as University College London Hospitals integrate pathology, radiology, and clinical data to define treatment intent.
Primary prevention emphasizes tobacco cessation programs promoted by World Health Organization and vaccination against HPV implemented in campaigns from ministries of health in Australia, United Kingdom, and United States. Alcohol reduction policies and public education initiatives by organizations like American Cancer Society target modifiable exposures. Screening in high‑risk populations—such as workers in specific industries, or cohorts in longitudinal studies at Framingham Heart Study‑style centers—remains controversial; opportunistic screening during dental visits at practices associated with American Dental Association can detect premalignant lesions.
Curative options include surgical resection with margin control and neck dissection performed by surgeons trained in programs at Harvard Medical School and University of Toronto, and definitive radiotherapy often combined with concurrent cisplatin‑based chemotherapy per protocols from European Society for Medical Oncology and National Comprehensive Cancer Network. Reconstructive techniques employ microvascular free flaps refined at centers such as Tokyo Medical and Dental University and University of Pittsburgh Medical Center. Recurrent or metastatic disease may be managed with immune checkpoint inhibitors (anti‑PD‑1 agents) approved following trials conducted by cooperative groups like European Organisation for Research and Treatment of Cancer and National Cancer Institute. Supportive care, speech and swallow rehabilitation, and survivorship services are coordinated with allied institutions including American Speech‑Language‑Hearing Association and cancer rehabilitation programs at University of Alabama at Birmingham.
Prognosis depends on stage, subsite, and HPV status; HPV‑positive oropharyngeal tumors generally carry better survival as reported in multicenter studies from Dana‑Farber Cancer Institute and Vanderbilt University Medical Center. Global incidence and mortality vary, with high burdens in regions documented by Global Burden of Disease Study and surveillance by International Agency for Research on Cancer; trends show declining tobacco‑related cases in some countries and rising HPV‑related oropharyngeal cancers in others, as described in analyses by Centers for Disease Control and Prevention and Public Health England. Five‑year survival ranges widely from favorable outcomes in early localized disease treated at specialty centers to poor survival in advanced metastatic presentations managed by palliative care services like those associated with St Christopher's Hospice.
Category:Cancers of the head and neck